15,000
Participants
Start Date
January 1, 2008
Primary Completion Date
September 30, 2024
Study Completion Date
October 30, 2024
Domperidone (drug)
The primary exposure of interest will be oral domperidone at a dose of 30 mg or more per day, which represents the median dose found in high-throughput computing analyses. For the primary comparison, oral domperidone at doses below 30 mg per day will be chosen to reduce the influence of indication bias.
London Health Sciences Centre Research Institute, London
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
OTHER